Triple-negative breast cancer (TNBC) is characterized by its highly heterogeneous microenvironment and propensity for aggressive behavior, both of which represent, along with poor prognosis and high incidence of relapse, the main challenges of curing the disease. Although recent progress in targeted
chemotherapy combinations has shown promising outcomes, conventional targeted chemotherapeutic approaches have relied on exploiting the expression of certain molecules or
proteins overexpressed on
cancer cells as
drug targets, which have demonstrated limited clinical benefit against metastatic
cancers. Here, we describe a tumoral
caspase-3 mediated
peptide-
doxorubicin conjugates (PDC) switch
therapy that adopts two different
caspase-3 cleavable PDCs, RGDEVD-DOX (TPD1) and EMC-KGDEVD-DOX (MPD1), for targeting metastatic
triple-negative breast cancer (mTNBC). First, using TPD1, an
integrin αVβ3 based targeted strategy was utilized to target
tumor cells or
tumor vasculature associated with the highly malignant progression of mTNBC. TPD1 triggered the
tumor cell-specific initial apoptosis and the induction of
caspase-3 expression in the target
tumor site. Then MPD1 was administered sequentially, which is an
albumin-binding
prodrug, and activated by induced
caspase-3 in order to maintain the tumoral
caspase-3 level and release the cytotoxic payload. The PDC switch
therapy markedly accumulated
doxorubicin in the
tumor site and augmented
tumor-specific in situ amplification of apoptosis. Importantly, the PDC switch
therapy exerted a bystander killing effect on the neighboring
cancer cells thus demonstrating potent therapeutic efficacy against both local and metastatic
cancers. Given the limited therapeutic outcomes with conventional targeted
therapies, our strategy of regulating the expression of
caspase-3 level as a
drug target could provide as a more durable and effective alternative in the treatment of highly heterogeneous mTNBC.